Models:
Philip Bordner
philipB/
NER-medical-text
0
Downloads: 1
Diff of /html_files/24898994.html [000000] .. [c0f169]

Switch to unified view

a b/html_files/24898994.html 

  1
  





  
  

  2
  
    <!DOCTYPE html>





  
  

  3
  
    <html>





  
  

  4
  
    <head>





  
  

  5
  
        <meta charset="utf-8">





  
  

  6
  
        <title>24898994 Visualization</title>





  
  

  7
  
    </head>





  
  

  8
  
    <body>





  
  

  9
  
        <h1>24898994 Visualization</h1>





  
  

  10
  
        <p><a href="main.html">Back to Main Page</a></p>





  
  

  11
  
        <div class="entities" style="line-height: 2.5; direction: ltr">A 





  
  

  12
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  13
  
    woman





  
  

  14
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sex</span>





  
  

  15
  
</mark>





  
  

  16
  
 in her 





  
  

  17
  
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  18
  
    60s





  
  

  19
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span>





  
  

  20
  
</mark>





  
  

  21
  
 was found to have 





  
  

  22
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  23
  
    screen





  
  

  24
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  25
  
</mark>





  
  

  26
  
 detected 





  
  

  27
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  28
  
    invasive





  
  

  29
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  30
  
</mark>





  
  

  31
  
 





  
  

  32
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  33
  
    lobular





  
  

  34
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  35
  
</mark>





  
  

  36
  
 





  
  

  37
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  38
  
    breast





  
  

  39
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  40
  
</mark>





  
  

  41
  
 





  
  

  42
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  43
  
    carcinoma





  
  

  44
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  45
  
</mark>





  
  

  46
  
 of the 





  
  

  47
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  48
  
    right





  
  

  49
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  50
  
</mark>





  
  

  51
  
 





  
  

  52
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  53
  
    breast





  
  

  54
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  55
  
</mark>





  
  

  56
  
 and 





  
  

  57
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  58
  
    invasive





  
  

  59
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  60
  
</mark>





  
  

  61
  
 





  
  

  62
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  63
  
    ductal





  
  

  64
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  65
  
</mark>





  
  

  66
  
 





  
  

  67
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  68
  
    carcinoma





  
  

  69
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  70
  
</mark>





  
  

  71
  
, 





  
  

  72
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  73
  
    no





  
  

  74
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  75
  
</mark>





  
  

  76
  
 





  
  

  77
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  78
  
    special





  
  

  79
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  80
  
</mark>





  
  

  81
  
 





  
  

  82
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  83
  
    type





  
  

  84
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  85
  
</mark>





  
  

  86
  
, of the 





  
  

  87
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  88
  
    left





  
  

  89
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  90
  
</mark>





  
  

  91
  
 





  
  

  92
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  93
  
    breast





  
  

  94
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  95
  
</mark>





  
  

  96
  
.</br>Staging 





  
  

  97
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  98
  
    CT





  
  

  99
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  100
  
</mark>





  
  

  101
  
 





  
  

  102
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  103
  
    imaging





  
  

  104
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  105
  
</mark>





  
  

  106
  
 prior to 





  
  

  107
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  108
  
    mastectomy





  
  

  109
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  110
  
</mark>





  
  

  111
  
 showed a 





  
  

  112
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  113
  
    12





  
  

  114
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Distance</span>





  
  

  115
  
</mark>





  
  

  116
  
 





  
  

  117
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  118
  
    cm





  
  

  119
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Distance</span>





  
  

  120
  
</mark>





  
  

  121
  
 





  
  

  122
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  123
  
    pelvic





  
  

  124
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  125
  
</mark>





  
  

  126
  
 





  
  

  127
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  128
  
    mass





  
  

  129
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  130
  
</mark>





  
  

  131
  
 which on initial impression was thought to be a 





  
  

  132
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  133
  
    fibroid





  
  

  134
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  135
  
</mark>





  
  

  136
  
 





  
  

  137
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  138
  
    uterus





  
  

  139
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  140
  
</mark>





  
  

  141
  
.</br>Associated 





  
  

  142
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  143
  
    postmenopausal





  
  

  144
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  145
  
</mark>





  
  

  146
  
 





  
  

  147
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  148
  
    bleeding





  
  

  149
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  150
  
</mark>





  
  

  151
  
 led to 





  
  

  152
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  153
  
    pelvic





  
  

  154
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  155
  
</mark>





  
  

  156
  
 





  
  

  157
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  158
  
    ultrasound





  
  

  159
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  160
  
</mark>





  
  

  161
  
, 





  
  

  162
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  163
  
    hysteroscopy





  
  

  164
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  165
  
</mark>





  
  

  166
  
 and 





  
  

  167
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  168
  
    biopsy





  
  

  169
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  170
  
</mark>





  
  

  171
  
.</br>The 





  
  

  172
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  173
  
    biopsy





  
  

  174
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  175
  
</mark>





  
  

  176
  
 showed 





  
  

  177
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  178
  
    undifferentiated





  
  

  179
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  180
  
</mark>





  
  

  181
  
 





  
  

  182
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  183
  
    sarcoma





  
  

  184
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  185
  
</mark>





  
  

  186
  
, 





  
  

  187
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  188
  
    unclassifiable





  
  

  189
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  190
  
</mark>





  
  

  191
  
 with 





  
  

  192
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  193
  
    immunohistochemistry





  
  

  194
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  195
  
</mark>





  
  

  196
  
.</br>Following discussion at a multidisciplinary team meeting it was felt that the 





  
  

  197
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  198
  
    uterine





  
  

  199
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  200
  
</mark>





  
  

  201
  
 





  
  

  202
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  203
  
    tumour





  
  

  204
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  205
  
</mark>





  
  

  206
  
 was a separate 





  
  

  207
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  208
  
    primary





  
  

  209
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  210
  
</mark>





  
  

  211
  
 





  
  

  212
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  213
  
    malignancy





  
  

  214
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  215
  
</mark>





  
  

  216
  
 rather than 





  
  

  217
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  218
  
    metastasis





  
  

  219
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  220
  
</mark>





  
  

  221
  
 from the 





  
  

  222
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  223
  
    breast





  
  

  224
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  225
  
</mark>





  
  

  226
  
.</br>





  
  

  227
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  228
  
    Hysterectomy





  
  

  229
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  230
  
</mark>





  
  

  231
  
 and 





  
  

  232
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  233
  
    bilateral





  
  

  234
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  235
  
</mark>





  
  

  236
  
 





  
  

  237
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  238
  
    salpingo





  
  

  239
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  240
  
</mark>





  
  

  241
  
-





  
  

  242
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  243
  
    oophorectomy





  
  

  244
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  245
  
</mark>





  
  

  246
  
 was performed for both treatment purposes and to fully categorise the malignancy to guide further 





  
  

  247
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  248
  
    adjuvant





  
  

  249
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  250
  
</mark>





  
  

  251
  
 





  
  

  252
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  253
  
    therapy





  
  

  254
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  255
  
</mark>





  
  

  256
  
.</br>





  
  

  257
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  258
  
    Histological





  
  

  259
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  260
  
</mark>





  
  

  261
  
 





  
  

  262
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  263
  
    examination





  
  

  264
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  265
  
</mark>





  
  

  266
  
 of the resection specimen showed a 





  
  

  267
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  268
  
    partially





  
  

  269
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  270
  
</mark>





  
  

  271
  
 





  
  

  272
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  273
  
    necrotic





  
  

  274
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  275
  
</mark>





  
  

  276
  
 





  
  

  277
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  278
  
    tumour





  
  

  279
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  280
  
</mark>





  
  

  281
  
 with a 





  
  

  282
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  283
  
    discrete





  
  

  284
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  285
  
</mark>





  
  

  286
  
 





  
  

  287
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  288
  
    outline





  
  

  289
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  290
  
</mark>





  
  

  291
  
 located within and extending throughout the 





  
  

  292
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  293
  
    myometrium





  
  

  294
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  295
  
</mark>





  
  

  296
  
.</br>The 





  
  

  297
  
<mark class="entity" style="background: #e3b5a4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  298
  
    tumour





  
  

  299
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Coreference</span>





  
  

  300
  
</mark>





  
  

  301
  
 was composed of 





  
  

  302
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  303
  
    malignant





  
  

  304
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  305
  
</mark>





  
  

  306
  
 





  
  

  307
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  308
  
    spindle





  
  

  309
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  310
  
</mark>





  
  

  311
  
 





  
  

  312
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  313
  
    cells





  
  

  314
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  315
  
</mark>





  
  

  316
  
 (figure 1A), with an intermittent component of 





  
  

  317
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  318
  
    pleomorphic





  
  

  319
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  320
  
</mark>





  
  

  321
  
 





  
  

  322
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  323
  
    cells





  
  

  324
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  325
  
</mark>





  
  

  326
  
 with abundant 





  
  

  327
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  328
  
    eosinophilic





  
  

  329
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  330
  
</mark>





  
  

  331
  
 





  
  

  332
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  333
  
    cytoplasm





  
  

  334
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  335
  
</mark>





  
  

  336
  
.</br>





  
  

  337
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  338
  
    Plentiful





  
  

  339
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  340
  
</mark>





  
  

  341
  
 





  
  

  342
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  343
  
    osteoclast





  
  

  344
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  345
  
</mark>





  
  

  346
  
-





  
  

  347
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  348
  
    like





  
  

  349
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  350
  
</mark>





  
  

  351
  
 





  
  

  352
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  353
  
    giant





  
  

  354
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  355
  
</mark>





  
  

  356
  
 





  
  

  357
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  358
  
    cells





  
  

  359
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  360
  
</mark>





  
  

  361
  
 were present (figure 1B).</br>





  
  

  362
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  363
  
    Mitoses





  
  

  364
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  365
  
</mark>





  
  

  366
  
 were 





  
  

  367
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  368
  
    numerous





  
  

  369
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  370
  
</mark>





  
  

  371
  
 and 





  
  

  372
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  373
  
    structurally





  
  

  374
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  375
  
</mark>





  
  

  376
  
 





  
  

  377
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  378
  
    abnormal





  
  

  379
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  380
  
</mark>





  
  

  381
  
 





  
  

  382
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  383
  
    forms





  
  

  384
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  385
  
</mark>





  
  

  386
  
 were common.</br>





  
  

  387
  
<mark class="entity" style="background: #e3b5a4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  388
  
    Neoplastic





  
  

  389
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Coreference</span>





  
  

  390
  
</mark>





  
  

  391
  
 





  
  

  392
  
<mark class="entity" style="background: #e3b5a4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  393
  
    cells





  
  

  394
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Coreference</span>





  
  

  395
  
</mark>





  
  

  396
  
 were surrounded by hyaline osteoid matrix and foci of coarse neoplastic woven bone (figure 1C).</br>Generous sampling of the tumour showed no admixed 





  
  

  397
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  398
  
    neoplastic





  
  

  399
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  400
  
</mark>





  
  

  401
  
 





  
  

  402
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  403
  
    epithelial





  
  

  404
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  405
  
</mark>





  
  

  406
  
 





  
  

  407
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  408
  
    elements





  
  

  409
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  410
  
</mark>





  
  

  411
  
, thus ruling out the more common carcinosarcoma (





  
  

  412
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  413
  
    malignant





  
  

  414
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  415
  
</mark>





  
  

  416
  
 





  
  

  417
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  418
  
    mixed





  
  

  419
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  420
  
</mark>





  
  

  421
  
 





  
  

  422
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  423
  
    Müllerian





  
  

  424
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  425
  
</mark>





  
  

  426
  
 





  
  

  427
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  428
  
    tumour





  
  

  429
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  430
  
</mark>





  
  

  431
  
).</br>





  
  

  432
  
<mark class="entity" style="background: #e3b5a4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  433
  
    Tumour





  
  

  434
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Coreference</span>





  
  

  435
  
</mark>





  
  

  436
  
 





  
  

  437
  
<mark class="entity" style="background: #e3b5a4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  438
  
    cells





  
  

  439
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Coreference</span>





  
  

  440
  
</mark>





  
  

  441
  
 showed 





  
  

  442
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  443
  
    immunohistochemical





  
  

  444
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  445
  
</mark>





  
  

  446
  
 





  
  

  447
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  448
  
    expression





  
  

  449
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  450
  
</mark>





  
  

  451
  
 for 





  
  

  452
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  453
  
    vimentin





  
  

  454
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  455
  
</mark>





  
  

  456
  
, 





  
  

  457
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  458
  
    smooth





  
  

  459
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  460
  
</mark>





  
  

  461
  
 





  
  

  462
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  463
  
    muscle





  
  

  464
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  465
  
</mark>





  
  

  466
  
 





  
  

  467
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  468
  
    actin





  
  

  469
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  470
  
</mark>





  
  

  471
  
 (





  
  

  472
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  473
  
    SMA





  
  

  474
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  475
  
</mark>





  
  

  476
  
), 





  
  

  477
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  478
  
    desmin





  
  

  479
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  480
  
</mark>





  
  

  481
  
 (





  
  

  482
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  483
  
    focally





  
  

  484
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  485
  
</mark>





  
  

  486
  
) and 





  
  

  487
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  488
  
    CD99





  
  

  489
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  490
  
</mark>





  
  

  491
  
.</br>





  
  

  492
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  493
  
    Epithelial





  
  

  494
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  495
  
</mark>





  
  

  496
  
 





  
  

  497
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  498
  
    markers





  
  

  499
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  500
  
</mark>





  
  

  501
  
 were 





  
  

  502
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  503
  
    not





  
  

  504
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  505
  
</mark>





  
  

  506
  
 





  
  

  507
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  508
  
    expressed





  
  

  509
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  510
  
</mark>





  
  

  511
  
.</br>The morphological and immunohistochemical appearances were in keeping with 





  
  

  512
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  513
  
    primary





  
  

  514
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  515
  
</mark>





  
  

  516
  
 





  
  

  517
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  518
  
    uterine





  
  

  519
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  520
  
</mark>





  
  

  521
  
 





  
  

  522
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  523
  
    osteoblastic





  
  

  524
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  525
  
</mark>





  
  

  526
  
 





  
  

  527
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  528
  
    variant





  
  

  529
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  530
  
</mark>





  
  

  531
  
 of 





  
  

  532
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  533
  
    osteosarcoma





  
  

  534
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  535
  
</mark>





  
  

  536
  
.</br>Unfortunately, despite treatment, further 





  
  

  537
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  538
  
    CT





  
  

  539
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  540
  
</mark>





  
  

  541
  
 





  
  

  542
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  543
  
    imaging





  
  

  544
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  545
  
</mark>





  
  

  546
  
 showed the development of 





  
  

  547
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  548
  
    multiple





  
  

  549
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  550
  
</mark>





  
  

  551
  
 





  
  

  552
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  553
  
    peritoneal





  
  

  554
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  555
  
</mark>





  
  

  556
  
 and 





  
  

  557
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  558
  
    pulmonary





  
  

  559
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  560
  
</mark>





  
  

  561
  
 





  
  

  562
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  563
  
    deposits





  
  

  564
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  565
  
</mark>





  
  

  566
  
, confirmed on 





  
  

  567
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  568
  
    biopsy





  
  

  569
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  570
  
</mark>





  
  

  571
  
 to be 





  
  

  572
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  573
  
    metastatic





  
  

  574
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  575
  
</mark>





  
  

  576
  
 





  
  

  577
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  578
  
    osteosarcoma





  
  

  579
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  580
  
</mark>





  
  

  581
  
.</br>The patient received 





  
  

  582
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  583
  
    palliative





  
  

  584
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  585
  
</mark>





  
  

  586
  
 





  
  

  587
  
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  588
  
    chemotherapy





  
  

  589
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span>





  
  

  590
  
</mark>





  
  

  591
  
 and 





  
  

  592
  
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  593
  
    died





  
  

  594
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Outcome</span>





  
  

  595
  
</mark>





  
  

  596
  
 





  
  

  597
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  598
  
    several





  
  

  599
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  600
  
</mark>





  
  

  601
  
 





  
  

  602
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  603
  
    months





  
  

  604
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  605
  
</mark>





  
  

  606
  
 





  
  

  607
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  608
  
    later





  
  

  609
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  610
  
</mark>





  
  

  611
  
.</br></div>





  
  

  612
  
    </body>





  
  

  613
  
    </html>





  
  

  614